Change in Preferred Drug List Status for Intranasal Rhinitis Agents
Date: September 30, 2025
Attention: All Providers
Effective date: September 29, 2025
Call to action: Texas Children’s Health Plan (TCHP) would like to inform providers that effective September 29, 2025, the Texas Health and Human Services Commission (HHSC) removed non-preferred status from generic azelastine/fluticasone nasal products on the preferred drug list (PDL). This change is in response to a shortage brand Dymista products.
| Impacted Medication | Type of Change | Effective Date |
| AZELASTINE/FLUTICASONE 137-50MCG SPR | Generic now preferred | September 29, 2025 |
How this impacts providers: The change will allow providers to prescribe the generic without requiring PDL prior authorization at this time and continue accessing necessary medication for their patients.
Next step for providers: Prescribers are encouraged to proactively obtain a prescription for the preferred alternatives to avoid disruption in patient’s therapy. Prescribers should share this communication with their staff.
If you have any questions, please email TCHP Pharmacy at: tchppharmacy@texaschildrens.org.
For access to all provider alerts: www.texaschildrenshealthplan.org/provideralerts.